Strategic Need Target ImaCor for expansion into hospitals that require continuous cardiac visualization at the bedside, highlighting the unique value of hTEE and the ClariTEE probe for ICU and perioperative care to drive adoption.

Upsell opportunity Position Zura handheld system alongside the disposable ClariTEE probe as a cost-effective, long-term monitoring solution for high-acuity patients, emphasizing reduced imaging downtime and improved patient management outcomes.

Clinical advantage Leverage the differentiator of continuous, direct cardiac visualization over time to address common clinical questions in critical care, enabling clinicians to optimize therapies at the bedside and potentially shorten ICU stays.

Growth potential Target mid to large hospitals and health systems with sizable ICU and perioperative volumes, using ImaCor’s mid-market revenue profile to propose scalable procurement and favorable service agreements as user adoption grows.

Strategic partnerships Explore collaborations with competing or adjacent high-volume medical device manufacturers and distributors, or with institutions already investing in advanced echocardiography, to accelerate distribution and bundled offerings for critical care imaging.